Posts

7 days in healthcare (January 2nd-8th, 2023)

 

Summary

From the point of view of Biomedicine, it is important to highlight significant advances in the treatment of some diseases, such as Alzheimer’s, breast cancer (a project inspired in its day by José Baselga), brain tumors, including the dreaded glioblastoma multiforme, and resistant tuberculosis.

With regard to Global Health, the WHO warns of global health threats in 2023: the Ebola outbreak in Uganda, which fortunately already seems to be in recession; the drought in the Horn of Africa; cholera, endemic in 69 countries; non-communicable diseases (particularly cardiovascular, diabetes, respiratory diseases and cancer), as well as the global stagnation due to the pandemic in the fight against various diseases: HIV, malaria and tuberculosis. Science reminds us that wastewater analysis has proven to be extremely useful for monitoring infectious diseases.

As for International Health Policy, with regard to covid, global concern is not so much for the cases that may come from China (which seem to correspond to the omicron that we already know) but for the new variant (Kraken) of United States, much more contagious than omicron and already affects a high percentage of cases in that country. The serious problems of the end of covid zero in China continue, with the opening of the country on January 8, which has been closed for three years. An editorial in The Economist looks at how the grand reopening may affect the global economy. Once again, the WHO says that mortality from covid in China is underestimated, if official figures are taken into account. Big change in the United States, where the abortion pill can be purchased in ordinary pharmacies. The large pharmacy chains, willing to participate in this sale. It must be remembered that a high percentage of abortions in the United States are already pharmacological. Serious crisis in the British National Health Service, with staff strikes, long waiting lists, saturation of emergencies and statements by unions and the Prime Minister. Labor wants to pass NHS employees to GPs (primary physicians), something that is in contradiction with the founding political pact of 1948 for the creation of the National Health Service, in which Aneurin Bevan participated. In France, health is also at the center of the political debate, with some statements on January 6 by President Macron, who considered among the solutions nothing less than ending fees per act, which in France are big words.

If we talk about National Health Policy (Spain), the year opens with the prospect of regional elections in 12 autonomous communities (May 28) and general elections at the end of the year, as well as a change in the head of the Ministry of Health. Several laws have been announced, including some advanced (new framework personnel statute, abortion, equity law), others more delayed (Public Health Agency, law of guarantees, possible reform of the dependency law). The Platform of Patient Organizations (POP) makes 10 proposals for chronic patients. As for professionals, some health insurance companies (DKV) have reacted quickly and announced increases in rates for doctors, which is undoubtedly a response to the criticism they had received from some medical associations, which even have raised certain protest actions. A piece of news says that the Zendal hospital has only 56 patients, which speaks of the fact that it has not yet found its place in Madrid’s health system, not surprising, since it seems that this hospital was established without the corresponding and obligatory Functional Plan (which defines the service portfolio, the population to be served, the incardination in the rest of the system, technology, personnel needs and other basic issues). Biosimilars, under the leadership of BIOSIM and starting in Extremadura, delve into the experience of shared benefit.

In the business sphere, in the international arena, Moderna acquires a genomics company. On the other hand, the completion of the Da Vinci robot patent will change the prospects for robotic surgery. At the national level, Ribera assumes the management of the Cascais hospital in Portugal, which is good news for public/private collaboration in our country.

Biomedicine

Global Health

International Health Policy

National health policy

Companies

7 days in healthcare (August 15-21, 2022)

Summary

From the point of view of biomedicine, the first drug is prepared using CRISPR (gene editing) technology. Important publication from The Lancet in the largest effort yet to identify risk factors in relation to cancer. Not surprisingly, however, tobacco and alcohol are the biggest risk factors, particularly tobacco.

As far as Global Health is concerned, polio is back and the UK is now offering vaccinations to children in London between the ages of 1 and 9.

Regarding international health policy, the famous North American Inflation Reduction Act has been signed by President Biden. Despite its name, the law has more to do with climate change and health, especially drug prices. No large growth in monkeypox is predicted, based on modeling carried out by The Economist. Deaths from covid remain high (15,000 a week globally) warns the Director General of the WHO. The Director of the American CDC denounces serious failures in the management of covid and announces substantial changes in the functioning of this body. A clear contrast to what is happening in Spain, where no conclusions seem to be drawn from the management of covid, despite being one of the most affected countries in terms of the number of cases and mortality in relation to the population.

If we talk about national health policy (Spain), the good news are that covid continues to decline, although there are still 62 deaths per day. The approval of the State Center for Public Health, scheduled for next week, is possibly the biggest consequence of covid. The birth rate in Spain falls to historical lows.

In the field of companies, drug prices break historical records in the USA. In Spain, HIPRA is preparing to manufacture 250 million doses of covid vaccines, pending approval by the EMA.

Biomedicine

Global Health

International health policy

National health policy

Companies